Eikon Therapeutics EIKN
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Jump To Section
$
About
Eikon Therapeutics (EIKN) Business Model and Operations Summary
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Key Insights
Eikon Therapeutics (EIKN) Stock Information & Key Business Metrics
Market Cap
$526.77 MillionTotal Outstanding Shares
54.14 Million SharesFree Float
26.60 Million Shares (49.1% Outstanding)Total Employees
384Current Dividend
No dividendIPO Date
February 5, 2026Headquarters
230 Harriet Tubman Way, Millbrae, CA, 94030